At Leerink Conference, ECYT said that despite of DSMB opined that Vintafolide alone is unlikely to be superior to Docetaxel alone, 80% of patients who were on Vintafolide remained on it ! (80% of patients didn't switch to Docetaxel). It means the physicians (clinical trial investigator) preferred Vintafolide over docetaxel, the current gold standard in 80% of the cases !!
It's likely to be due to better tolerability of Vintafolide compared to Docetaxel rather than efficacy.
Anyways, It's very positive in my opinion.
The real suspense is the combo arm (vinta+doce). I like the suspense !!!
I believe it will achieve all endpoints by huge margins.